Novo Nordisk Shares Drop After Drug Candidate Fails in Cardiovascular Trial

By Adria Calatayud

 

Novo Nordisk shares fell after the Danish drugmaker said an experimental medicine didn't reduce risk of major adverse cardiovascular events in a late-stage trial.

Shares in Novo Nordisk were down 9.5% in European afternoon trading.

The company said the drug, ziltivekimab, didn't achieve the expected risk reduction for adverse cardiovascular events in patients with atherosclerotic cardiovascular disease, chronic kidney disease and inflammation.

In the phase 3 trial, overall rates of adverse events were similar for people treated with ziltivekimab and those that took placebo, Novo Nordisk said.

The company said it remains committed to cardiovascular disease and that it plans to continue two additional trials testing ziltivekimab in people with heart failure and in people who suffered an acute heart attack. Results are due in the first half of next year, it added.

 

Write to Adria Calatayud at adria.calatayud@wsj.com

 

(END) Dow Jones Newswires

July 31, 2026 07:54 ET (11:54 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.

Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.

Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.

Popular

Sponsor Center